For the first time, the U.S. Food and Drug Administration has approved a drug that uses 3D printing technology, paving the way for potential customization of drugs to suit patients’ needs.

The drug, Spritam levetiracetam, made by privately held Aprecia Pharmaceuticals Co, was approved for oral use as a prescription adjunctive therapy in the treatment of epilepsy, the company said on Monday.

3D printing could help companies make products “to the specifications of an individual patient rather than (take a) one-size-fits-all kind of approach,” Wedbush Securities analyst Tao Levy said.

3D printers help make products by layering material until a three-dimensional object is created.

In the healthcare industry, these printers are used by dentists to create replicas of jaws and teeth as well as some finished dental implants and orthopedic surgeons have tested them to make customized hip replacements.

British scientists have also used 3D printing to create personalized replica models of cancerous parts of the body to allow doctors to target tumors more precisely.